Table 3.
Clinicopathological and treatment-related factors associated with OS after GTC treatment
| Characteristics | Number of patients | Median OS (months) | Survival rate (%) | P | ||
|---|---|---|---|---|---|---|
| 1-year | 2 years | 3 years | ||||
| Age (years) | 0.624 | |||||
| ≤60 | 15 | 14.0 | 60.0 | 6.7 | 0.0 | |
| >60 | 17 | 14.0 | 64.7 | 12.9 | 6.5 | |
| CEA concentration (ng/ml) | 0.275 | |||||
| ≤5 | 20 | 13.0 | 55.0 | 11.1 | 5.6 | |
| >5 | 12 | 17.0 | 75.0 | 8.3 | 0.0 | |
| CA19-9 concentration (ng/ml) | 0.835 | |||||
| ≤15 | 21 | 14.0 | 76.2 | 10.3 | 5.2 | |
| >15 | 11 | 14.0 | 54.5 | 9.1 | 0.0 | |
| Child–Pugh grade | 0.381 | |||||
| A | 27 | 14.0 | 55.6 | 8.0 | 4.0 | |
| B | 5 | 16.0 | 100.0 | 20.0 | 0.0 | |
| Gastric cancer | ||||||
| Tumor size (cm) | 0.358 | |||||
| <6 | 18 | 14.0 | 72.2 | 18.1 | 6.0 | |
| ≥6 | 14 | 12.0 | 50.0 | 14.3 | 0.0 | |
| Tumor location | 0.294 | |||||
| Upper | 11 | 6.0 | 56.3 | 7.1 | 7.1 | |
| Not upper | 21 | 12.0 | 68.8 | 25.0 | 0.0 | |
| Depth of invasion | 0.744 | |||||
| Non-T4b | 20 | 14.0 | 65.0 | 5.0 | 5.0 | |
| T4b | 12 | 12.0 | 50.0 | 20.0 | 0.0 | |
| Lymph node metastasis | 0.211 | |||||
| Absent | 5 | 17.0 | 80.0 | 20.0 | 20.0 | |
| Present | 27 | 14.0 | 55.6 | 7.9 | 0.0 | |
| Histological differentiation | 0.338 | |||||
| Well, moderately | 7 | 12.0 | 42.9 | 14.3 | 0.0 | |
| Poorly, undifferentiated | 25 | 14.0 | 68.0 | 12.8 | 4.3 | |
| Liver metastases | ||||||
| Size of liver metastases (cm) | 0.025* | |||||
| <3 | 17 | 12.0 | 70.6 | 9.3 | 6.4 | |
| ≥3 | 15 | 6.0 | 46.7 | 6.7 | 0.0 | |
| Extent of liver metastases | 0.002* | |||||
| H1 | 7 | 23.0 | 71.4 | 42.9 | 4.3 | |
| H2 | 12 | 13.0 | 58.3 | 8.3 | 0.0 | |
| H3 | 13 | 10.0 | 46.0 | 0.0 | 0.0 | |
| Radiofrequency ablation | 0.013* | |||||
| Not performed | 29 | 14.0 | 58.6 | 14.7 | 0.0 | |
| Performed | 3 | 31.0 | 100.0 | 33.3 | 33.3 | |
OS: Overall survival; GTC: Gastrectomy, TACE, Chemotherapy; CEA: Carcinoembryonic antigen. *P<0.05.